Study of Nuwiq Recombinant Factor VIII With Emicizumab to Prevent Bleeding in Males Over 12 With Severe Hemophilia A Undergoing Major Surgery
Led by Octapharma · Updated on 2026-05-12
28
Participants Needed
18
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the overall perioperative haemostatic effectiveness of Nuwiq, a recombinant factor VIII, combined with emicizumab prophylaxis in male patients aged 12 and older with severe haemophilia A undergoing major surgery. The study is a prospective, open-label, multinational, multicentre, single-arm trial focused on patients receiving emicizumab who require additional FVIII during surgery.
Participants will receive Nuwiq intravenously following the approved prescribing information. Treatment will be administered every 8 to 24 hours as needed until adequate wound healing is achieved. If necessary, treatment may continue for at least another 7 days to maintain factor VIII plasma levels between 30 and 60 IUdL. This regimen aims to provide effective haemostatic cover throughout the surgical and healing period.
Throughout the study, participants will be monitored during surgery and until wound healing is complete, typically within 30 days after surgery. Assessments include measuring haemostatic efficacy during and after surgery, blood product transfusion levels, factor VIII plasma levels, thrombin generation, and monitoring for thrombotic events, inhibitor formation, and adverse events. The study duration covers the surgical procedure and a follow-up period to ensure safety and treatment response.
CONDITIONS
Brief Title
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
Research Team
S
Sigurd Knaub, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Nuwiq plus emicizumab
Standard FVIII replacement
What this option is
The study uses Nuwiq (recombinant FVIII) given perioperatively in people with severe hemophilia A already on emicizumab prophylaxis
Standard care involves perioperative factor VIII replacement for hemophilia A patients on emicizumab prophylaxis undergoing major surgery
Purpose
To assess overall perioperative hemostatic efficacy of Nuwiq in addition to emicizumab during major surgery
Maintain adequate hemostasis during surgery in hemophilia A patients even when on emicizumab, using factor VIII replacement
How it is given
Nuwiq administered perioperatively in combination with ongoing emicizumab as per protocol
Factor VIII replacement given peri‑ and post‑operatively as clinically indicated
Evidence status
Prospective single‑arm data are being collected to evaluate efficacy
Historical and practice‑based evidence supports efficacy of perioperative FVIII replacement in surgical settings
Limitations
Single‑arm design without randomized comparison limits formal efficacy comparison
Retrospective/practice data lack controlled assessment and may vary by institution
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 12Years +
MALE
Eligibility Criteria
You may qualify if you...
Male patients aged 12 years or older
Severe haemophilia A with factor VIII activity less than 1% based on medical history
Previous treatment with any factor VIII product for at least 150 exposure days
On regular emicizumab prophylaxis for at least 1 month before scheduled major elective surgery requiring factor VIII
Provided freely given written informed consent according to local regulations
You will not qualify if you...
Presence of any coagulation disorder other than haemophilia A
Present or past factor VIII inhibitor at or above 0.6 Bethesda units per milliliter
Severe liver or kidney disease defined by elevated liver enzymes or creatinine above 120 µmol/L
Known allergy to Nuwiq or its ingredients such as sucrose, sodium chloride, calcium chloride dihydrate, arginine hydrochloride, sodium citrate dihydrate, or poloxamer 188
Previous surgery within this study
Current participation in another interventional clinical trial
Treatment with any investigational medicinal product within 30 days before screening visit
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Repeated every 8-24 hours until adequate wound healing, then for at least another 7 days if required
Participants receive Nuwiq, a recombinant factor VIII, administered intravenously around the time of major surgery to provide haemostatic cover in combination with their regular emicizumab prophylaxis.
Multiple visits during surgery and post-operative period up to approximately 30 days
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Open-Label Study Evaluating Safety and Effects of Marstacimab Following Emicizumab Discontinuation in Males with Severe Hemophilia A
Observing Changes in Anti-factor VIII Antibodies During Emicizumab Treatment
in Patients with Severe Hemophilia A
Study of Nuwiq Recombinant Factor VIII With Emicizumab to Prevent Bleeding in Males Over 12 With Severe Hemophilia A Undergoing Major Surgery
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
NuPOWER (Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis): protocol for an open-label, single-arm, multicentre study.